huIL1B/huTFRC Mouse

Interleukin-1β (IL-1β), encoded by the IL1B gene, is a cytokine with potent pro-inflammatory activity that plays a central role in inflammatory responses and innate immune regulation. It induces the release of various inflammatory mediators and activates immune cells, participating in the regulation of biological processes such as cell proliferation, differentiation, apoptosis, and febrile responses ^[1-2]. Studies have shown that abnormal expression or activity of IL-1β is closely associated with various pathological processes, including cryopyrin-associated periodic syndromes (CAPS), gout, rheumatoid arthritis (RA), recurrent pericarditis, type 2 diabetes mellitus (T2DM), and other inflammatory and autoimmune diseases, while also playing an important role in the pathogenesis of multiple malignancies and neurodegenerative diseases ^[3-4]. Transferrin receptor 1 (TFRC) is a transmembrane protein widely expressed across diverse cells and tissues, playing a critical role in iron transport and the maintenance of iron homeostasis. It is highly expressed on brain capillary endothelial cells, making it a vital target for drug delivery across the blood-brain barrier (BBB) ^[5-6]. In recent years, TFRC-mediated receptor-mediated transcytosis (RMT) has become a key strategy for improving the delivery efficiency of therapeutic antibodies and other macromolecular drugs across the BBB. In neuroinflammatory diseases such as multiple sclerosis (MS), IL-1β can promote microglial activation, induce pathogenic Th17 cell responses, increase BBB permeability, and facilitate the recruitment of inflammatory cells, thereby driving central nervous system inflammation and demyelinating injury ^[7-8].

The huIL1B/huTFRC mouse is a dual-gene humanized model obtained by crossing the huIL1B mouse (Catalog No.: C001791) with the huTFRC mouse (Catalog No.: C001860). Co-expressing human IL1B and TFRC targets, this model can be utilized for the screening, pharmacodynamic evaluation, safety assessment, and mechanism-of-action studies of IL1B/TFRC-targeted drugs. Meanwhile, it is suitable for evaluating the trans-BBB delivery capacity of therapeutic agents, providing an ideal preclinical research platform for the development of innovative therapies for neuroinflammatory diseases, such as multiple sclerosis (MS).